Journal article

Bleeding and thrombotic risk in pregnant women with Fontan physiology

A Girnius, D Zentner, AM Valente, PG Pieper, KE Economy, M Ladouceur, JW Roos-Hesselink, C Warshak, SL Partington, Z Gao, N Ollberding, M Faust, S Girnius, H Kaemmerer, N Nagdyman, S Cohen, M Canobbio, T Akagi, J Grewal, E Bradley Show all

Heart | BMJ PUBLISHING GROUP | Published : 2021

Abstract

Background/objectives Pregnancy may potentiate the inherent hypercoagulability of the Fontan circulation, thereby amplifying adverse events. This study sought to evaluate thrombosis and bleeding risk in pregnant women with a Fontan. Methods We performed a retrospective observational cohort study across 13 international centres and recorded data on thrombotic and bleeding events, antithrombotic therapies and pre-pregnancy thrombotic risk factors. Results We analysed 84 women with Fontan physiology undergoing 108 pregnancies, average gestation 33±5 weeks. The most common antithrombotic therapy in pregnancy was aspirin (ASA, 47 pregnancies (43.5%)). Heparin (unfractionated (UFH) or low molecula..

View full abstract

University of Melbourne Researchers